End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2,439 MXN | -1.49% | -3.04% | -7.83% |
07:30pm | Transcript : Johnson & Johnson Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 01:30 PM | |
05:04pm | J&J: encouraging results in the treatment of depression | CF |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an enterprise value anticipated at 3.85 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.83% | 347B | - | ||
+39.03% | 727B | C+ | ||
+30.57% | 592B | B | ||
+15.46% | 319B | B- | ||
-0.48% | 274B | C+ | ||
+12.55% | 238B | B+ | ||
+6.65% | 204B | B- | ||
-6.09% | 203B | A+ | ||
-3.12% | 160B | C+ | ||
-2.28% | 120B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJ * Stock
- Ratings Johnson & Johnson